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ABSTRACT  
Objective: The PPARG SNP rs1801282 (Pro12Ala C>G) has shown variable association with 
metabolic syndrome traits in healthy subjects. We investigated genotype association with 
plasma lipids and the influence of dietary polyunsaturated:saturated fat ratio (P:S) in subjects 
at increased cardiometabolic risk. 
 
Methods: Habitual dietary intake was recorded at recruitment to the RISCK Study. PPARG 
rs1801282 was genotyped in 466 subjects aged 30-70 y. Genotype associations with plasma 
lipids were assessed at recruitment, after a 4-wk high-SFA (HS) diet and a 24-wk intervention 
with reference (HS), high-MUFA (HM) and low-fat (LF) diets. The interaction of habitual P:S 
intake x genotype on plasma lipid concentrations was investigated. 
 
Results: PPARG rs1801282 G-allele frequency was 0.09. At recruitment, G-allele carriers had 
higher plasma total cholesterol concentration (n=415; P=0.05) after adjustment for BMI, 
gender, age and ethnicity. Dietary P:S ratio x genotype interaction influenced plasma LDL-
cholesterol (P=0.02) and triglyceride (P=0.03) concentrations. At P:S ratio ≤0.33, mean LDL-
cholesterol concentration in G-allele carriers was higher than in non-carriers, but fell between 
0.34-0.65. Triglyceride concentration followed a similar pattern. After the 4-wk HS diet, G-
allele carriers had higher concentrations of total cholesterol (P=0.03), LDL-cholesterol 
(P=0.04) and apo B (P=0.04) than non-carriers, after adjustments. After the 24-wk 
interventions, diet x genotype interaction did not significantly influence either LDL-
cholesterol (P=0.58) or triglyceride (P=0.57) concentrations. 
 
Conclusion: A high dietary P:S ratio would help to reduce plasma LDL-cholesterol and 
triglyceride concentrations in PPARG rs1801282 G-allele carriers at increased 
cardiometabolic risk.  
Keywords: Peroxisome proliferator-activated receptor-γ (PPARγ); Single nucleotide 
polymorphism; Polyunsaturated fatty acid; Saturated fatty acid; Gene-nutrient-interaction. 
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1. Introduction 
 
The transcription factor peroxisome proliferator-activated receptor-γ (PPARγ) is one of three 
PPARs and a member of the nuclear hormone receptor superfamily [1]. The major natural 
ligands are polyunsaturated fatty acids and prostanoids [2], suggesting a role in transducing 
nutritional to metabolic signals [3]. An increase in PPARγ mRNA in adipose tissue of mice 
exposed to a high fat diet [4] suggested that dietary modulation might influence adipogenesis 
induced by PPARγ in response to raised plasma concentration of fatty acid ligands.  
Variants of the PPARγ2 gene PPARG could alter transcriptional activity of the 
activator through DNA- and/or ligand-binding affinity. The Pro12Ala C>G polymorphism 
(rs1801282) is present at a frequency of approximately 7.6 % in Caucasians (NCBI SNP 
database http://www.ncbi.nlm.nih.gov/snp build 132 accessed 15/12/10). Previous studies 
have investigated PPARG rs1801282 genotype associations with risk of obesity and diabetes,  
with equivocal results [5, 6, 7] suggesting that environmental influences such as dietary intake 
may be involved. Luan et al. [8] found BMI in G-allele carriers but not CC homozygotes, was 
influenced by ratio of habitual dietary polyunsaturated:saturated fatty acid intake (P:S). 
Others showed a relationship between intake of total fat and BMI [9] or waist circumference 
[10] in common CC homozygotes, but not in G-allele carriers. However, when MUFA rather 
than total fat was examined [9], intake was found to be inversely associated with BMI in G-
allele-carriers and not in CC homozygotes. In vitro, the PPARγ2 Ala-variant exhibits reduced 
binding to DNA and modest impairment of transcriptional activation following treatment with 
pharmacological ligand thiazolidinediones (TZDs) [11, 12]. This raised the possibility that 
differential responses by CC homozygotes and G-allele carriers to unsaturated fatty acid 
ligands of PPARγ might influence adipogenesis. 
PPARγ target genes include several involved in cholesterol and triglyceride 
metabolism [13, 14, 15]. We hypothesised that dietary intake of unsaturated fats might 
interact with PPARG rs1801282 genotype to influence concentration of plasma lipids. We 
have investigated 466 men and women aged 30-70 y at increased risk of metabolic syndrome 
in the RISCK Study [16]. We tested association of genotype with plasma lipids at recruitment 
screening (habitual diet), after 4 wk on a diet high in SFA (HS diet) and with changes in lipid 
concentrations after a 24-wk intervention with reference (HS), high-MUFA (HM) and low-fat 
(LF) diets. We also examined the influence of interaction between genotype and BMI, gender, 
ethnicity and habitual dietary P:S ratio on concentration of  plasma lipids. 
 
2. Methods 
2.1 Subjects  
Ethical approval for the RISCK study (ISRCTN29111298) was granted from the National 
Research Ethics Service and written informed consent from participants was obtained, 
including subsequent genetic analyses. Men and women (age range: 30-70 y) recruited from 
the general population, attended a clinic in a fasting state at the participating centres 
(University of Reading, Imperial College London, University of Surrey and the Medical 
Research Council Human Nutrition Research Unit [MRC-HNR] and Kings College London). 
Eligibility for entry to the study was assessed by a point system and implementation of 
exclusion criteria described previously [16]. 549 subjects completed the study. Self-reported 
ethnicity was recorded as White, South Asian, Black African, or ‘other’.  
 
2.2 Study design  
The RISCK study is a parallel 2 × 2 factorial design compared with a control intervention 
[16]. At screening, unweighed 4-d food diaries (3 weekdays and 1 weekend day) were 
collected to record the habitual diet. Nutrient intakes were estimated by using the food-
composition database software DINO as described previously [17]. The intervention diets 
were planned to provide similar intakes of dietary energy but to vary in the amount and type 
of fats and carbohydrates. All participants followed a 4-wk run-in period during which they 
consumed a high-saturated fat ‘reference diet’ before being randomised to the reference diet 
or one of four isoenergetic dietary interventions designed to lower saturated fat. In this study, 
the dietary intervention groups differing in carbohydrate quality were combined to focus the 
analyses on the manipulation of dietary fat. The resulting three dietary groups were: high 
saturated fat ‘reference diet’ (HS) designed to reflect a higher saturated fat intake than 
habitual ‘Western’ diet (~18% of energy SFA, 12% MUFA, 38% total fat, 45% CHO), ‘high-
MUFA diet’ (HM) in which SFA was reduced and replaced with MUFA (~10% of energy 
SFA, 20% MUFA, 38% total fat, 45% CHO) and ‘low-fat diet’ (LF), in which SFA was 
reduced through replacement of total fat with carbohydrate (~10 % of energy SFA, 11% 
MUFA, 28% total fat, 55% CHO). The dietary intervention is described in detail elsewhere 
[17]. Measurements made after the run-in diet are referred to as ‘baseline’. All participants 
followed their randomly prescribed diets for 24 wk, after which a further blood sample was 
collected and anthropometry measured. Weight (in light clothing) and height (without shoes) 
were measured. An indwelling venous cannula was inserted into the forearm. 
 
2.2 Biochemical analysis 
Blood samples for analysis were drawn after a minimum 8-h overnight fast and serum was 
stored at -45 °C until analyzed. Fasting lipids including total cholesterol, HDL-cholesterol and 
triglycerides were measured as described previously [16].  LDL-cholesterol was derived from 
the Friedwald equation.   
 
2.3 DNA extraction and genotyping 
Buffy coats removed from blood samples were stored in EDTA at -20°C. Genomic DNA was 
extracted from 200 µl buffy coat using an Illustra blood genomic prep mini spin kit (GE 
Healthcare, Amersham, UK) according to manufacturer’s instructions. The PPARG 
rs1801282 SNP was genotyped by KBiosciences (Hoddesdon, UK). Genotype accuracy as 
assessed by inclusion of duplicates in the array was 98% and negative controls (water blanks) 
were included on each plate. Genotyping success rate was 89%. 
  
2.4 Statistical analysis  
PPARG rs1801282 genotype distributions were tested for deviation from the Hardy-Weinberg 
equilibrium by a χ2 test with 1 df (P > 0.05). Statistical analyses were carried out using the 
SPSS version 17.0 for Windows (SPSS Inc, Chicago, IL, USA). Where needed, variables 
were log transformed to obtain better approximations of the normal distribution prior to 
analysis.  Data were analyzed by using analysis of covariance (ANCOVA) with ethnicity, 
BMI, age, gender and diet as covariates. Outliers were excluded from the ANCOVA and were 
defined as points >2.5 times the interquartile range from the median on the transformed scale 
at recruitment or after HS diet. All data presented in text and tables are expressed as means or 
geometric means ± SD or 95% CI. Statistical significance was taken at P < 0.05. 
 
3. Results  
3.1. Characteristics of subjects 
A total of 549 subjects completed the study and data from 548 subjects were analyzed. Based 
on self-reported ethnicity, individuals of White, S. Asian, Black African and ‘other’ ancestry 
were distinguished. 47.5% of the subjects had metabolic syndrome according to the criteria of 
the International Diabetes Federation [18].  The characteristics at recruitment of the 
participants who completed the study are presented in Table 1.   
 
3.2. PPARG rs1801282 allele and genotype frequencies 
All available DNA samples were genotyped (n = 466) and data was obtained for 415 subjects. 
Table 2 shows the allele and genotype frequencies for PPARG rs1801282 in subjects stratified 
by ethnic group. Genotype distributions did not deviate from Hardy-Weinberg expectations. 
The minor allele frequencies were similar to those listed on the NCBI SNP database 
(http://www.ncbi.nlm.nih.gov/snp; build 132 accessed 15/12/10). The G-allele was more 
frequent than expected in White Europeans (0.10 in RISCK compared to 0.076 in HapMap-
CEU (European)) and absent in Black Africans, as in Hap-Map trios (HapMap-YRI (Sub-
Saharan African)). There are no comparative data available for S. Asians. 
 
3.3. PPARG rs1801282 genotype associations with phenotypes at recruitment screening 
Table 3 shows anthropometry and plasma lipid concentrations in subjects at recruitment 
screening with respect to PPARG rs1801282 genotype. Carriers of the minor G-allele had 
significantly higher plasma total cholesterol concentration compared to non-carriers, after 
adjustment for BMI, gender, age and ethnicity.  
 
3.4. Interaction between PPARG rs1801282 genotype and habitual dietary P:S ratio 
There was a significant interaction between dietary P:S ratio and genotype as determinants of 
plasma LDL-cholesterol (P = 0.02) and triglyceride (P = 0.03) concentrations. Figure 1 shows 
plasma LDL-cholesterol and triglyceride concentrations adjusted for BMI, age, gender and 
ethnicity, with respect to PPARG rs1801282 genotype in quartiles of P:S intake. There were a 
number of significant differences in concentration of LDL-cholesterol and triglycerides in G-
allele carriers between quartiles of P:S ratio as shown in Figure 1 and detailed in OSM Table 
1. When the P:S ratio was low (≤ 0.33), mean plasma LDL-cholesterol concentration in G-
allele carriers was higher than in non-carriers, but fell by up to 17% through the remaining 
quartiles. There was a difference of only 9% in LDL-cholesterol concentration in non-carriers 
across all quartiles. Plasma triglyceride concentration in G-allele carriers in the lowest quartile 
of P:S intake was 21.4% lower than in non-carriers. In the second quartile (0.34 to 0.47) G-
allele carriers had higher mean concentration than non carriers, but showed a fall of 35.3% 
from second to fourth (>0.65) quartile. There was 0% difference in triglyceride concentration 
in non-carriers between second and fourth quartiles. 
 
3.5. Change in plasma lipid concentrations after dietary intervention  
After the 4-wk run-in on HS diet, subjects were randomly assigned to continuation on the HS 
reference diet or the HM or LF diets. The HM group had lower plasma phospholipid %SF 
than the LF group (P ≤ 0.03) and higher %MUFA (P = 0.0001). The dietary interventions did 
not affect other fatty acid classes [(n-3) PUFA, (n-6) PUFA and trans FA] [17]. Total 
cholesterol and LDL-cholesterol concentrations were significantly lower with the HM and LF 
than the HS diet (P < 0.001 and P < 0.001). Apo B concentrations differed between treatment 
groups (P < 0.001) and were lower with the HM and LF diets than with the HS diet. HDL 
cholesterol concentrations were lower with the LF than with the HS or HM diets (P < 0.001 
and P = 0.002, respectively). There were no significant changes in concentration of plasma 
triglycerides following interventions [16].  
 
3.6. PPARG rs1801282 genotype associations with plasma lipid concentrations at baseline  
Table 4 shows anthropometry and plasma lipid measurements with respect to PPARG 
rs1801282 genotype after the 4-wk HS diet at baseline. Carriers of the minor G-allele had 
significantly higher plasma total cholesterol, LDL-cholesterol and apo B concentrations than 
non-carriers, after adjustment for gender, BMI, age and ethnicity.  
 
3.7. PPARG rs1801282 genotype associations with change in plasma lipid concentrations 
after dietary intervention  
In order to investigate the effect of decrease in SFA without alteration in MUFA intake, we 
compared change in plasma lipid concentrations after continuation on the HS and switching to 
LF diet (18% versus 10% SFA), with respect to PPARG rs1801282 genotype. Both diets 
contained the same proportion of PUFA. There was no significant difference in the change in 
either plasma LDL-cholesterol or triglyceride concentration with respect to genotype (n = 
244, respectively P = 0.48 and P = 0.86) after adjustment for change in BMI, age, gender and 
ethnicity. To examine the effect of increased intake of MUFA without alteration in SFA, we 
compared change in plasma lipid concentrations after the HM and LF diets (20% versus 11% 
MUFA), which also contained the same proportion of PUFA. There was no significant 
difference in the change in either plasma LDL-cholesterol or triglyceride concentrations with 
respect to genotype (respectively n = 338, P = 0.34; n = 340, P = 0.24) after adjustments. 
Interaction between the three diets and genotype did not significantly influence either LDL-
cholesterol (P = 0.58) or triglyceride concentrations (P = 0.57). 
 
4. Discussion  
Numerous studies have investigated associations between PPARG Pro12Ala (rs1801282 
C>G) and risk of obesity and diabetes, with equivocal outcomes. One meta-analysis of studies 
of type 2 diabetes has found a significant increase in risk with the Pro12 allele [5] but another 
revealed no significant effect on related traits [6]. Contrary findings of associations with 
obesity have also been reported [7]. These inconsistencies suggest that environmental 
modifiers of the effects of genetic variation in PPARγ2 may be involved. We have 
investigated associations between PPARG rs1801282 genotype and plasma lipid 
concentrations in subjects at risk of the metabolic syndrome, following habitual intake and 
dietary interventions differing in proportions of saturated and unsaturated fatty acids. After 
the habitual diet, minor G-allele carriers had significantly higher plasma total cholesterol 
concentration than non-carriers and the dietary P:S ratio interacted with genotype to influence 
the concentrations of plasma LDL-cholesterol and triglyceride. After the HS diet, G-allele 
carriers had significantly higher plasma total cholesterol, LDL-cholesterol and apo B 
concentrations. A decrease in SFA intake after the HM and LF diets had no significant effect 
on either plasma LDL-cholesterol or triglyceride concentrations. 
Memisoglu et al. [9] found total fat intake was inversely correlated with total plasma 
cholesterol in PPARG rs1801282 CC subjects but no effect among G-allele-carriers. They 
were the first to report an interaction between genotype and intake of MUFA, which was 
inversely associated with BMI in G-allele-carriers, but not in CC homozygotes. Thus, the 
responsiveness of G-carriers to dietary manipulation only emerged when MUFA rather than 
total fat intake was analysed. Luan et al. [8] had previously shown greater sensitivity of G-
allele carriers to dietary PUFA in determination of BMI. Without reference to diet, genotype 
was not significantly associated, but interaction between the P:S ratio and genotype in 
determining BMI was highly significant (n = 592, P = 0.0038).  As the ratio of P:S increased, 
BMI decreased in G-allele carriers but not in CC homozygotes. Both findings [8, 9] are 
compatible with unsaturated fats acting as specific ligands for PPARγ [2] and lower 
transcriptional activity of the PPARγ-Ala variant reducing PPARγ-mediated adipogenesis 
[11].  
Our study is the first to report significant interaction between the P:S ratio and PPARG 
rs1801282 genotype influencing plasma LDL and triglyceride concentrations. Switching from 
habitual to HS diet was accompanied by an increase in plasma LDL in carriers of the less 
transcriptionally active PPARγ-Ala variant, compared to those homozygous for the normal 
PPARγ-Pro. As the P:S ratio increased beyond the first P:S quartile, the concentration of 
plasma LDL-cholesterol  fell by 17% in G-carriers and by only 9% in CC homozygotes.  
When PUFA replaces SFA in the diet, the major portion of cholesterol lowering is seen in the 
LDL fraction, with reduction in circulating particles revealed by a fall in apo B concentration 
[19]. This occurs primarily through receptor-mediated clearance of LDL, by reversing 
suppression of receptor activity induced by SFA [20]. Expression of the LDL receptor gene is 
activated by sterol regulatory element-binding protein-2 (SREBP-2) [21]. Insulin-induced 
gene INSIG1, the key regulator of SREBP activity, is up-regulated by activation of PPARγ 
[13]. PPARγ activation by troglitazone has been shown to reduce nuclear SREBP-2 and 
down-regulate LDL clearance from plasma by the liver LDL receptor [22]. The less active 
PPARγ-Ala variant would be expected to bind to the INSIG1 PPRE with less affinity then the 
Pro variant. As a result, G-carriers would express less Insig-1, SREBP2 activity would be 
higher, and increased expression of the LDLR gene would lead to increased LDL-cholesterol 
clearance from the plasma. As the PPARγ PUFA ligand concentration increased, the 
difference in abilities of the Pro- and Ala- variants to increase transcriptional activity could 
become more pronounced. In the highest P:S quartile we found plasma LDL-cholesterol 
concentration was significantly higher in carriers of the PPARγ-Ala variant. Hamada et al. 
[23] showed G-allele carriers have a significantly larger electrophoretic sub-fractional area of 
small dense lipoprotein (sdLDL4-7) particles than those with the CC genotype, suggesting 
impaired ability to clear this atherogenic LDL sub-fraction in particular.  
Lipoprotein lipase activity is a rate-limiting determinant of triglyceride hydrolysis in 
plasma. Plasma triglyceride concentration in G-allele carriers fell consistently beyond the 
second P:S quartile. It is well known that n-3 fatty acids decrease the concentration of serum 
triglycerides [24]. PPARγ may mediate this effect, since PUFAs are PPARγ ligands [2] and 
LPL is a PPARγ target gene [15]. Lindi et al. [25] found a significantly greater decrease in 
serum triglyceride concentration in healthy G-allele carriers than in CC homozygotes in 
response to n-3 fatty acid supplementation, when the total dietary fat intake was below 37% 
energy intake or the intake of SFA was below 10%. This is consistent with our finding of a 
fall in plasma triglyceride concentration in G-allele carriers as P:S intake increased. However, 
both results suggest that the G-allele is associated with increased LPL activity in the presence 
of high PUFA and by implication, higher transactivation of the LPL gene by the PPARγ Ala- 
variant, contrary to findings in vitro [11, 12]. Lindi et al. [25] found no difference in post-
heparin plasma LPL activity following placebo or fatty acid supplementation, suggesting that 
any change in LPL expression elicited by PPARγ was not functionally significant. An 
explanation of the genotype x diet interaction which significantly influenced plasma 
triglyceride concentration is not evident at present.  
We found that G-allele carriers had significantly higher plasma total cholesterol, LDL-
cholesterol and apo B concentrations, compared to CC homozygotes after the 4-wk HS diet. 
An increase in plasma cholesterol by dietary SFA is well established [20]. Hence, a shift from 
a mean ~13% of energy SFA in the habitual intake [17] to ~18% of energy SFA on the HS 
diet would be expected to increase plasma cholesterol. As SFAs bind to PPARγ with less 
affinity than PUFAs [2], increasing SFA would reduce activation of the receptor. The PPARγ 
Pro- and Ala-variants do not differ in their affinities for pharmacological ligands, but the Ala- 
variant has lower affinity for target gene PPREs [11]. Both variants could show lower 
activation as SFA intake increases but gene activation by the Ala-variant would remain lower 
than by the Pro form. On the HS diet, G-carriers had 5.4% higher total cholesterol and 5.7% 
higher LDL-cholesterol, but 11% higher apo B than CC homozygotes. This suggests a higher 
number of plasma LDL-particles were circulating in carriers of the less transcriptionally 
active PPARγ-Ala variant.   
In order to establish whether effects of interaction between with the P:S ratio of 
habitual intake and genotype that we had observed were related to increased  PUFA, as  
distinct from decreased SFA, we first compared change in plasma lipid concentrations after 
HS and LF diets, in which SFA was reduced and MUFA remained constant. Carriage of the 
G-allele was not significantly associated with change in either plasma LDL-cholesterol or 
triglyceride concentrations, so the decrease in SFA had no significant effect. We obtained the 
same results when we compared changes in lipids after HM and LF diets, in which MUFA 
was raised and SFA remained constant. An increase in MUFA might have been expected to 
have had an effect, but they are weaker PPARγ activators than PUFAs [2]. Therefore we 
cannot confirm that the interaction between the P:S ratio of habitual intake and PPARG 
rs1801282 genotype in determining plasma LDL-cholesterol and triglyceride concentrations 
depends specifically on an increase in consumption of PUFA, but it does appear that it does 
not depend on a decrease in SFA. 
Limitations of our study include a relatively small sample size and the small observed 
changes in plasma lipid concentrations. Wide inter-individual variation in concentrations 
could have limited the significance of associations with phenotype. The significance of the 
effect of dietary P:S x gene interactions on plasma LDL-cholesterol and triglyceride 
concentrations should be treated with caution, as they were of modest significance in mainly 
overweight subjects. If substantiated in a larger cohort, a recommendation to PPARG 
rs1801282 G-allele carriers to maintain a high dietary intake of PUFA:SFA, to reduce plasma 
concentrations of atherogenic LDL-cholesterol and triglycerides, would be justified. 
Identification of individuals who are genetically more likely to respond to particular dietary 
changes may be important for successful intervention in the prevention of cardiovascular 
disease.  
 
Source of funding 
Supported by the UK Food Standards Agency (project NO2031) (GF, BAG, JAL, SAJ, 
TABS). Foods were supplied by Unilever Food and Health Research Institute (Unilever R&D, 
Vlaardingen, Netherlands), Cereal Partners UK (Welwyn Garden City, Hertfordshire, United 
Kingdom), Grampian (Banff, United Kingdom), Weetabix Ltd (Kettering, United Kingdom) 
and Sainsbury’s Supermarkets Ltd (London, United Kingdom). AA was supported by a 
studentship from the Saudi Arabian Ministry of Higher Education. The funding sources had 
no role in the study design, in the collection, analysis and interpretation of data, in the writing 
of the report or in the decision to submit the paper for publication. 
 
 
Acknowledgements 
We acknowledge the contributions of the additional RISCK Study Group members - 
University of Reading: Hannah Farrant (local coordinator); Claire Lawrence, Edel Magee, and 
Kit Tsoi (research assistants); Darren Cole (database manager); Anna Gent, Celia Greenberg, 
and Caroline Stokes (coding and analyses of dietary data); Mario Siervo and Rosemary Hall 
(clinicians); Imperial College London: Louise Goff (local coordinator); Claire Howard, 
Namrata Dhopatkar and Bushra Siddiqui (research assistants); Anne Dornhurst (clinician); 
Kings College London: Fiona Lewis (local coordinator) Samantha Bowen, L Chen and Robert 
Gray (research assistants); Roy Sherwood (sample analyses of clinical biochemistry); 
Anthony Leeds, A Shah, G Saran, J Niehuser-Saran, and JA Cockburn (clinicians); University 
of Reading: Rachel Gitau (local coordinator); Katie Newens and Sean Lovegrove (research 
assistants); University of Reading and University of Surrey: John Wright (clinician); 
University of Surrey: Margaret Griffin (local coordinator).  
 
Conflicts of interest 
The authors and their research groups have a number of links with the food industry. In a 
personal capacity, GSF is a consultant to Coca-Cola, Premier Foods, and Unilever and TABS 
has acted as a consultant to Seven Seas and is a member of the Scientific Advisory Committee 
for the Global Dairy Platform and external scientific review committee of the Malaysian Palm 
Oil Board, and chairs Cadbury's Global Nutrition Advisory Panel. TABS, BAG, JAL, SAJ 
and GSF have received ad hoc honoraria for lectures or writing articles. In a non-personal 
capacity, BAG was formerly a member of an expert group known as the Fat Panel, which was 
supported by Dairy Crest, Kerry Gold, and Unilever; SAJ is a member of Scientific Advisory 
Boards for Coca-Cola, Heinz, PepsiCo, Nestlé and Kellogg's. SAJ sits on UK government 
advisory boards that also include food industry members. All research groups received 
products from a range of food companies gratis for research purposes, including Archer 
Daniel Mills, Croda, Matthews Foods, Nestle, PepsiCo, Jordan, GSK, and Unilever. AA and 
SDO reported no conflicts of interest.  
 
Appendix A Supplementary data associated with this article: OSM Table 1. 
 
REFERENCES   
1. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of 
metabolism. Endocr Rev 1999;20:649-88. 
 
2. Xu HE, Lambert MH, Montana VG et al. Molecular recognition of fatty acids by 
peroxisome proliferator-activated receptors. Mol Cell 1999;3:397-403. 
 
3. Semple RK, Chatterjee VK, O’Rahilly S. PPARγ and human metabolic disease. J Clin 
Invest 2006;116:581-89. 
 
4. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B et al. 
Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 
1996;97:2553-61. 
 
5. Altshuler D, Hirschhorn JN, Klannemark M et al. The common PPARgamma Pro12Ala 
polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80. 
 
6. Tonjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in 
peroxisome proliferator-activated receptor gamma with Prediabetic phenotypes: meta-analysis 
of 57 studies on nondiabetic individuals. Diabetes Care 2006;29:2489-97. 
 
7. Masud S, Ye S, SAS Group. Effect of the peroxisome proliferator activated receptor-
gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 
2003;40:773-80. 
 
8. Luan J, Browne PO, Harding AH, Halsall DJ, O'Rahilly S, Chatterjee VK, Wareham NJ. 
Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 2001;50:686-89. 
 
9. Memisoglu A, Hu FB, Hankinson SE et al. Prospective study of the association between 
the proline to alanine codon 12 polymorphism in the PPARgamma gene and type 2 diabetes. 
Diabetes Care 2003;26:2915-17. 
 
10. Robitaille J, Despres JP, Perusse L, Vohl MC. The PPAR-gamma P12A polymorphism 
modulates the relationship between dietary fat intake and components of the metabolic 
syndrome: results from the Quebec Family Study. Clin Genet 2003;63:109-116. 
 
11. Deeb SS, Fajas L, Nemoto M et al. A Pro12Ala substitution in PPARgamma2 associated 
with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat 
Genet 1998;20:284-87.  
 
12. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine 
substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on 
thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000;268:178-82. 
 
13.  Kast-Woelbern HR, Dana SL, Cesario RM et al. Rosiglitazone induction of Insig-1 in 
white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor 
gamma and sterol regulatory element-binding protein in the regulation of adipogenesis. J Biol 
Chem 2004;279:23908-15.  
 
14. Ogata M, Tsujita M, Hossain MA et al. On the mechanism for PPAR agonists to enhance 
ABCA1 gene expression. Atherosclerosis 2009;205:413-9. 
 
15. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM et al. PPARα and PPARγ activators 
direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase 
gene. EMBO J 1996; 15:5336-48. 
 
16. Jebb SA, Lovegrove JA, Griffin BA et al. Effect of changing the amount and type of fat 
and carbohydrate on insulin sensitivity and cardiovascular risk: the RISCK (Reading, 
Imperial, Surrey, Cambridge, and Kings) trial. Am J Clin Nutr 2010;92:748-58.  
 
17. Moore C, Gitau R, Goff L, et al. Successful manipulation of the quality and quantity of fat 
and carbohydrate consumed by free-living individuals using a food exchange model. J Nutr 
2009;139:1534-40. 
 
18. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome–a new world-wide definition. A 
consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469-80. 
 
19. Vega GL, Groszek E, Wolf R, Grundy SM. Influence of polyunsaturated fats on 
composition of plasma lipoproteins and apolipoproteins. J Lipid Res 1982;23:811-22. 
 
20. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res 
1990;31:1149-72. 
 21. Hua X, Yokoyama C, Wu J, Briggs MR, Brown MS, Goldstein JL, Wang X. SREBP-2, a 
second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding 
to a sterol regulatory element. Proc Natl Acad Sci USA 1993;90:11603-7. 
 
22. Klopotek A, Hirche F, Eder K. PPAR gamma ligand troglitazone lowers cholesterol 
synthesis in HepG2 and Caco-2 cells via a reduced concentration of nuclear SREBP-2. Exp 
Biol Med (Maywood) 2006;231:1365-72. 
 
23. Hamada T, Kotani K, Tsuzaki K et al. Association of Pro12Ala polymorphism in the 
peroxisome proliferator-activated receptor gamma2 gene with small dense low-density 
lipoprotein in the general population. Metabolism 2007;56:1345-49. 
 
24. Harris WS, Lu G, Rambjor GS, Walen AI, Ontko JA, Chang Q, Windsor SL. Influence of 
n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Am J Clin Nutr 
1997;66:254-260. 
 
25. Lindi V, Schwab U, Louheranta A et al. Impact of the Pro12Ala polymorphism of the 
PPAR-gamma2 gene on serum triacylglycerol response to n-3 fatty acid supplementation. 
Mol Genet Metab 2003;79:52-60. 
 
 
 
 
 
 
Table 1 
Characteristics of RISCK study subjects at recruitment screening  
Phenotype 
Male 
(n = 230 ) 
Female 
(n = 318) 
Ethnicity1 [n (%)]   
    White European 192 (83.5) 249 (78.3) 
    South Asian  21 (9.1) 31 (9.7) 
    Black African  12 (5.2) 28 (8.8) 
    Other  5 (2.2) 10 (3.2) 
Age (y) 52 ± 10 51 ± 9 
Waist circumference (cm) 102 ± 10  94 ± 12 
BMI (kg/m2) 28.3±3.8 28.6±5.3 
Triglycerides (mmol/L) 1.4±0.8 1.2±0.7 
Total cholesterol (mmol/L) 5.5±0.9 5.5±1.0 
LDL-cholesterol (mmol/L) 3.6±0.8 3.5±0.9 
HDL-cholesterol (mmol/L) 1.2±0.3 1.5±0.4 
Data measured at recruitment is presented for all subjects who completed 
the study (n = 548).Values are mean ± SD. 1Self-reported ethnicity.  
 
 
 
 
 
 
 
 
Table 2 
PPARG rs1801282 allele and genotype frequencies  
 Ethnic group1 
 S. Asian 
[n (%)] 
Black 
African       
[n (%)] 
White 
European       
[n (%)] 
Other 
[n (%)] 
All 
[n (%)] 
 44 (9) 38 (8) 366 (79) 18 (4) 466 (100) 
MAF 0.07 0.0 0.10 0.10 0.09 
CC  36 (86) 36 (100) 258 (80) 12 (80) 342 (82) 
CG  6 (14) 0 (0) 61 (19) 3 (20) 70 (17) 
GG  0 (0) 0 (0) 3 (1) 0 (0) 3 (1) 
Total  42 (100) 36 (100) 322 (100) 15 (100) 415 (100) 
All subjects for whom DNA samples were available were genotyped (n = 466); n (%) is 
number of each ethnic group genotyped, as % of total.  Total with genotype data (n = 415); n 
(%) refers to number of each genotype obtained, with % genotype frequency. MAF Minor 
allele frequency; C = major allele; G = minor allele.  1Self-reported ethnicity. 
 
 
 
 
 
 
 
 
 
Table 3 
Associations between PPARG rs1801282 genotypes and phenotypes at recruitment  
 PPARG rs1801282 genotype   P 
Phenotype CC CG + GG   
Males n (%) 132 (77) 40 (23)   
Females n (%) 210 (86) 33 (14)   
BMI (kg/m2) 29.0 (28.5,29.4) 28.0 (26.9,29.0)  0.10 
Waist circumference (cm) 98.5 (97.2,99.8) 97.9 (95.1,100.7)  0.16 
Body fat (%) 34.6 (33.6,35.6) 31.6 (29.5,33.7) 
 
0.26 
Total cholesterol (mmol/L) 5.5 (5.4,5.6) 5.7 (5.5,6.0) 
 0.05 
Triglycerides (mmol/L) 1.3 (1.2,1.3) 1.3 (1.2,1.5)  0.57 
HDL-cholesterol (mmol/L) 1.4 (1.3,1.4) 1.4 (1.3,1.4)  0.92 
LDL-cholesterol (mmol/L) 3.4 (3.3,3.5) 3.6 (3.4,3.8)  0.16 
Data is presented for subjects for whom genotypic and phenotypic data was available (n = 
415). Mean (95% CI), or GM mean (95% CI) values for triglycerides and HDL-cholesterol, 
stratified by genotype are shown at recruitment. Association was tested by univariate analysis 
of variance based on a dominant model. P-values adjusted for BMI, age, gender and 
ethnicity, shown in bold when nominally significant (< 0.05). 
 
 
 
 
 
 
 
 
Table 4  
Association between PPARG rs1801282 genotype and phenotypes after HS diet 
 PPARG rs1801282 genotype  P 
Phenotype CC CG + GG   
Males n (%) 132 (77) 40 (23)   
Females n (%) 210 (86) 33 (14)   
BMI (kg/m2) 28.8 (28.3,29.3) 27.9 (26.9,29.0)  0.14 
Waist circumference (cm) 97.9 (96.6,99.3) 98.4 (95.5,101.3)  0.48 
Body fat (%) 34.3 (33.4,35.2) 31.6 (29.7,33.6)  0.25 
Total cholesterol (mmol/L) 5.5 (5.4,5.6) 5.8 (5.6,6.0) 
 0.03 
Triglycerides (mmol/L) 1.3 (1.3,1.4) 1.4 (1.3,1.6)  0.26 
HDL-cholesterol (mmol/L) 1.4 (1.3,1.4) 1.4 (1.3,1.4)  0.85 
Apolipoprotein A1 (g/L) 1.2 (1.2,1.2) 1.2 (1.2,1.3)  0.57 
LDL-cholesterol (mmol/L) 3.5 (3.4,3.6) 3.7 (3.5,3.9) 
 0.04 
Apolipoprotein B (g/L) 0.95 (0.92,0.98) 1.03 (0.96,1.10) 
 0.03 
Data is presented for subjects for whom genotypic and phenotypic data was available (n = 
415). Mean (95% CI), or GM mean (95% CI) values for triglycerides and HDL-cholesterol, 
stratified by genotype are shown after 4 wk on HS diet. Association was tested by univariate 
analysis of variance based on a dominant model. P-values adjusted for BMI, age, gender and 
ethnicity, shown in bold when nominally significant (< 0.05). 
 
 
 
Figure legend 
 
Figure 1.  (A) Mean plasma LDL-cholesterol and (B) triglyceride concentrations with respect 
to quartiles of habitual dietary P:S ratio and PPARG rs1801282 genotype. C = major allele; G = 
minor allele. Number of genotyped subjects (n = 415) with plasma lipid measurements in each 
quartile of P:S ratio ≤0.33, 0.34-0.47, 0.48-0.65, >0.65 was as follows: (A) LDL-cholesterol: 
88, 105, 102, 101 (n = 396); (B) Triglycerides: 88, 103, 101, 101 (n = 393). Mean concentration 
of LDL-cholesterol and geometric mean concentration of triglycerides are shown. Bars 
represent 95% CI. In CG + GG subjects, significant differences in LDL-cholesterol 
concentration with respect to P:S ≤0.33 and in triglycerides with respect to P:S >0.65 are shown 
*P < 0.05; **P < 0.01. 
 
 
